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Abstract 
Background: Enterovirus 71 (EV71) is the most common causative pathogens of hand, foot and mouth disease 
(HFMD) associated with severe neurological complications. There is a great need to develop prophylactic vaccine 
against EV71 infection.
Results: EV71 virus-like particle (VLP) was produced in yeast expression system by the co-expression of four EV71 
structural proteins VP1–VP4. Immunization with the recombinant VLPs elicited potent anti-EV71 antibody responses 
in adult mice and anti-VLP sera were able to neutralize EV71 virus in vitro. Neonatal mice model demonstrated VLP 
immunization conferred protection to suckling mice against the lethal viral challenge.
Conclusions: Co-expression of four EV71 structural proteins VP1–VP4 in yeast expression systems is an effective 
method to produce EV71 VLPs. VLP-based vaccine shows great potential to prevent EV71 infection.
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Background
Human enterovirus 71 is a non-enveloped RNA virus of 
the Picornaviridae family that was first reported in 1969. 
The virion is around 25–30 nm in diameter containing a 
single-stranded RNA viral genome of approximately 7500 
nucleotides [1–3]. EV71 encoded a single large polypro-
tein that is initially cleaved into P1, P2, and P3 regions. 
The P1 region is subsequently processed by protease 3CD 
to generate four capsid subunit proteins, VP1 to VP4. The 
viral genome is packaged in an icosahedral capsid which 
is composed of 60 copies of structural proteins. High-
resolution structural analysis showed that VP1-3 form a 
pseudo T = 3 icosahedral capsid that are located on the 
surface of viral capsid [4]. VP4 is myristoylated at the N 
terminus and located inside virion [5, 6]. However, crys-
tallographic analysis demonstrated that the structure of 
mature EV71 virion is similar to other enteroviruses [7].
EV71 has been identified as one of the major etiologi-
cal agents of hand, foot and mouth disease (HFMD) [8, 
9]. A number of HFMD epidemics caused by EV71 infec-
tion occurred in the Asia–Pacific region and are asso-
ciated with severe neurological complications such as 
aseptic meningitis, poliomyelitis-like paralysis and brain-
stem encephalitis. The surveillance data from National 
Center for Disease Control and Prevention showed that 
more than 3 million HFMD cases and 1384 deaths were 
reported by the end of 2010 in mainland China [10–14]. 
HFMD is becoming the most common viral disease in 
these areas that seriously threat children health. How-
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Vaccination is the most optimal way to prevent and 
reduce prevalence of viral infectious diseases. Neutral-
izing antibody plays an essential role in the protection 
of suckling mice against EV71 infection, because immu-
nization of maternal mice with inactivated EV71 can 
confer protection to neonatal mice against EV71 lethal 
challenge [15]. Several linear immunodominant epitopes 
were screened and successfully identified in EV71 struc-
tural proteins [16–20]. In recent years, recombinant 
virus-like particle (VLP)-based vaccine strategies have 
been frequently used for novel vaccine design. Vaccines 
based on viral VLPs have been successfully used in pre-
vention against hepatitis B virus and human papillomavi-
rus [21–23]. VLPs are empty non-infectious viral capsids 
that structurally mimic the conformation of native virion. 
High density of viral linear and conformational epitopes 
on the VLP surface may elicit strong immune responses 
[23]. In the present study, EV71 VLPs were successfully 
produced by co-expression of four structural viral pro-
teins in yeast, which is safe, reliable and cost-effective 
platform for recombinant protein production.
Results
Generation and characterization of EV71 VLPs
EV71 capsid is composed of 60 copies of each of the four 
viral structural proteins VP1, VP2, VP3 and VP4. In the pre-
sent study, genes encoding VP1, VP2, VP3 and VP4 proteins 
of EV71 were inserted into vectors for co-expression of four 
viral proteins in yeast (Fig. 1). The expressions of viral pro-
teins were investigated by SDS-PAGE and Western-blot. 
Viral proteins were purified using the method described 
previously with modification [3] and visualized using SDS-
PAGE analysis. Three bands were observed which corre-
sponded to VP1, VP2 and VP3 of EV71 virus, respectively, 
according to the molecular weight of each band (Fig.  2a). 
However, the band corresponding to EV71 VP2 protein was 
further proofed by using VP2-specific antibody MAB979 
by Western-blot (Fig.  2b). To determine whether the co-
expression of four viral structural proteins can generate 
EV71 VLPs, total proteins of yeast cells were extracted and 
loaded onto the sucrose and cesium chloride gradient to iso-
late EV71 VLPs by ultracentrifugation. As shown in Fig. 2c, 
the formation of viral VLPs were observed in purified yeast 
lysates by transmission electron microscope and the diam-
eters of particles were about 25–27 nm which appeared ico-
sahedral. Our data indicate that co-expression of four viral 
structural proteins VP1, VP2, VP3 and VP4 in yeast cells 
can definitely lead to the formation of EV71 VLPs.
VLP immunization elicits neutralizing antibody responses 
against EV71
To investigate whether the EV71 VLPs were capable of 
inducing anti-EV71 antibody responses, female BALB/c 
mice were immunized i.m. with either purified VLPs, 
denatured VLPs or inactivated EV71 virus at the dose 
of 20 μg/mouse and received booster injections 3 weeks 
later. Mice immunized with yeast cell lysates and PBS 
were used as negative controls. The immunized animals 
were bled at week 0, 2, 5, 8 for serological analysis. The 
results showed that anti-EV71 IgG antibodies became 
detectable in mice immunized by EV71 VLPs, denatured 
VLPs and inactivated-EV71 virus at 2 weeks after inocu-
lation. The titers were enhanced by booster injection and 
reached a maximum titration at week 5. No anti-EV71 
antibody response was detected in the yeast cell lysates-
immunized group and the PBS group (Fig. 3). Our results 
demonstrated that EV71 VLPs, denatured VLPs and inac-
tivated-EV71 virus induced similar levels of anti-EV71 
antibody.
To evaluate whether the antibodies were able to neu-
tralize EV71 virus, mouse serum samples were twofold 
serially diluted and mixed with infectious EV71 (100 
TCID50) to test their ability to neutralize the live EV71 
virus in  vitro. EV71 Bj08 (genotype C4) and a variant 
of the prototype strain of EV71, BrCr-TR (genotype A) 
were used for in vitro neutralization assay. As shown in 
Fig.  4, remarkable increase in anti-EV71 neutralizing 
antibody titers was observed after the booster injection 
at 3 weeks post-injection. The EV71 VLPs elicited slightly 
higher neutralization titers against EV71 Bj08 compared 
to the heat-inactivated EV71. The denatured VLPs elic-
ited lower neutralization titers than the purified VLPs, 
although they induced similar levels of IgG antibodies. 
These data are consistent with the previous report [3]. 
In vitro inhibition of EV71-mediated cytopathic effect 
(CPE) by anti-sera was illustrated by microscopic photo-
graphs. Serum samples were diluted 256-fold for neutral-
ization assay. Virus-mediated CPE was remarkably found 
in cells infected by either EV71 Bj08 or BrCr-TR (Fig. 5a, 
b) after 6 days of infection. In contrast, no obvious CPE 
was observed in the cells without viral infection (Fig. 5c, 
d). Virus-induced CPE could be significantly suppressed 
by the addition of anti-VLP sera (Fig. 5e, f ) and anti-inac-
tivated EV71 sera (Fig. 5g, h). Lower suppression of CPE 
was observed by using anti-denatured VLP sera (Fig. 5i, 
j), suggesting that antibody recognizing conformational 
viral epitopes are essential for VLP-induced immune pro-
tection against EV71.
In vivo protection against lethal viral challenge in neonatal 
mouse model
The in  vivo protective ability of anti-sera against lethal 
EV71 challenge was evaluated in a neonatal mouse 
model and EV71 BrCr-TR was used as a representa-
tive high-virulence strain. 10 LD50 of BrCr-TR virus 
was mixed with sera from mice immunized with EV71 
Page 3 of 9Wang et al. BMC Res Notes  (2016) 9:42 
VLPs, inactivated-EV71 virus, yeast cell lysates and PBS. 
The mixture of EV71 virus and anti-sera was incubated 
overnight at 37  °C and used to inoculate intraperito-
neally (i.p.) 1-day-old BALB/c suckling mice (n  =  10 
per group). Infection by BrCr-TR viral strain was used 
as positive control. The data showed that 90  % of mice 
treated with EV71 virus mixed with the EV71 VLPs- and 
inactivated-EV71 virus-immune sera remained healthy 
and survived until the end of the experiments. In con-
trast, mice inoculated with virus mixed with the yeast cell 
lysates and PBS-immune sera died at 16 days post-inoc-
ulation, indicating that EV71 VLPs and inactivated EV71 
virus conferred immune protection against EV71 lethal 
challenge in vivo (Fig. 6).
Fig. 1 Schematic illustration of the construction of recombinant plasmids
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Discussion
Vaccination is a commonly used and cost-effective 
method for infectious disease control. Various types of 
vaccine candidates against EV71 have been evaluated in 
animal model, including recombinant subunits [15, 24], 
synthetic peptide vaccines [18–20], live attenuated vac-
cines [25, 26], VLP vaccines [3, 27, 28], DNA vaccines 
[29] and formalin-inactivated virion vaccines [30–33]. 
Recombinant subunit vaccines can be produced from 
different expression systems. It has been found that 
EV71 capsid proteins VP1, VP2 and VP3 are immuno-
genic and capable of eliciting antibodies that recognize 
their corresponding viral proteins. Unlike VP2 and VP3, 
recombinant VP1 was capable of eliciting effective neu-
tralizing antibody responses against EV71 [34]. Synthetic 
peptides containing neutralization epitopes are consid-
ered as good vaccine candidates providing well-defined 
immunogens and safety advantages. Two linear neutral-
izing epitopes SP70 and SP55 found in EV71 VP1, were 
capable of inducing neutralizing antibody responses in 
mice against EV71 virus by inhibiting viral infection at 
pre- or post-attachment steps [35]. Our previous study 
showed that immunization of N terminus of EV71 VP4 
elicits cross-protective antibody responses [36]. Recently, 
a cross-neutralizing epitope was identified in EV71 VP2 
[37]. However, neutralizing antibody responses induced 
by peptides are usually weak and require strong adju-
vants. Live attenuated vaccines are widely used for viral 
disease prevention, however, the emergence of  patho-
genic viral revertants has raised vaccine safety concerns. 
Inactivated vaccine and VLP-based vaccine retain both 
Fig. 2 Viral protein expression and electron microphotographs. a The expressions of EV71 structure proteins were visualized by SDS-PAGE. b The 
expression of EV71 VP2 was monitored using VP2-specific antibody MAB979 by Western blot. EV71 VLPs were isolated using sucrose and discon-
tinuous cesium chloride (CsCl) gradient (1.4, 1.33, 1.29 and 1.25 g/ml) by ultracentrifugation. The formation of EV71 VLPs in yeast was monitored by 
electronic microscope. Size bar 50 nm
Fig. 3 Kinetics of antibody titer development in mice following 
immunization. The inactivated EV71 virus was coated on the plate 
surface to capture anti-EV71 antibody. The data were represented by 
the mean of reciprocal log2 endpoint titers ± standard deviation (SD)
Fig. 4 Kinetics of neutralizing antibodies to EV71 following 
immunization. In vitro microneutralization assay was used to detect 
neutralizing antibodies in the sera from immunized mice. The 
neutralizing antibody titer was defined as the highest serum dilution 
that prevented the occurrence of cytopathic effects. The data was 
represented by the mean of endpoint titers ± SD
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linear and conformational neutralizing epitopes respon-
sible for eliciting potent neutralizing antibody responses 
against viral infection [38] and are thus widely accepted 
as effective vaccine candidates. VLP-based vaccine has a 
safety advantage over inactivated vaccine due to the lack 
of the viral genome.
Recombinant VLPs that mimic the conformation of 
authentic native viruses can be produced from variable 
expression systems such as insect cells, yeast and E. coli. 
EV71 VLPs have been successfully produced in vari-
able expression systems via co-expression of P1 and 3CD 
viral proteins [28, 39]. 3CD is an EV71-encoded pro-
tease responsible for the digestion of P1 polyprotein into 
structural subunit proteins, which form EV71 capsids via 
self-assembly.
Two types of EV71 viral particles (E- and F-particles) 
have previously been produced from Vero cells cultured 
in a serum-free condition. SDS-PAGE and Western blot 
analysis illustrated that the E-particle was an immature 
particle containing incompletely cleaved VP0 protein, 
while in F-particle, VP0 protein was fully cleavaged 
into VP2 and VP4 by autocatalytic processing. In addi-
tion, neutralization assay showed that the inactivated 
F-particle induced a more potent neutralizing antibody 
response against EV71 in the mouse model than the 
E-particle [40]. Thus, F-particle of EV71 is an ideal vac-
cine candidate to prevent EV71 infection. In the present 
study, we report a technique for production of EV71 
F-particles in yeast cells. TEM analysis showed that EV71 
VLPs were successfully generated in yeast cells through 
the co-expression of four EV71 capside proteins (VP1 to 
VP4) without using 3CD protease. It has been reported 
that host cell apoptosis can be triggered by the coxsacki-
evirus B3-encoded protease and HIV-encoded proteases 
induced cell death [41, 42]. Co-expression of P1 protein 
and 3CD can be used to produce EV71 VLP in different 
host cells. However, the effects of EV71-encoded pro-
tease on host cell apoptosis or death still remains to be 
elucidated.
EV71 is phylogenetically classified into three distinct 
genotypes: A, B, and C based on the genetic variation 
of VP1 sequences. Genotypes B and C can be further 
divided into B1–B5 and C1–C5 subgenotypes, respec-
tively [43, 44]. Recently, 3 new genotypes were reported, 
D, E and F subgenotypes [45, 46]. An ideal anti-EV71 
vaccine should be able to provide broad protective activ-
ity against a wide spectrum of EV71 strains. One sin-
gle serotype was reported in EV71 when measured by 
hyperimmune animal sera. However, antigenic variations 
have been identified recently in post-infection human 
sera when measured cross-neutralizing antibody titers 
against different EV71 genotype strains. Antigenic vari-
ation among different genogroups was reported [47]. 
Immunization of live attenuated EV71 vaccine (genotype 
Fig. 5 In vitro neutralization assay. a Cells infected by EV71 Bj08 strain. b Cells infected by EV71 BrCr-TR strain. c, d Uninfected cells. e Cells infected 
by Bj08 strain reacted with anti-VLP serum. f Cells infected by BrCr-TR strain reacted with anti-VLP serum. g Cells infected by Bj08 reacted with 
anti-inactivated EV71 serum. h Cells infected by BrCr-TR strain reacted with anti-inactivated EV71 serum. i Cells infected by Bj08 reacted with anti-
denatured VLP serum. j Cells infected by BrCr-TR strain reacted with anti-denatured VLP serum. Size bar 50 μm
Fig. 6 Suckling mouse was used as a model to assess neutralizing 
effects of anti-sera. Groups of 1-day-old BALB/c suckling mice were 
inoculated intraperitoneally (i.p.) with the mixture of virus and anti-
sera. Survival rates were recorded daily after infection for 16 days. 10 
mice were used for each group
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A) induced the strongest neutralizing antibody responses 
against the homotype (genotype A) and weaker neutral-
izing antibody responses against other EV71 genotype 
strains such as B1, B4, C2 and C4, suggesting antigenic 
heterogeneity among EV71 isolates [26]. Five EV71 vac-
cine candidates are currently being evaluated in clini-
cal trial. Genotype C4 and B4 viruses were selected for 
anti-EV71 vaccine development in mainland China and 
Taiwan, respectively. The inactivated EV71 C4 genotype 
vaccine could provide homogeneous and broad cross-
protection against different subgenotypes of EV71 such 
as B4, B5, C2, C4 and C5 strains in health children and 
infants [48]. An potent cross-neutralizing antibody pro-
tection against EV71 subgenotypes B1, B4, B5 and C4A 
were also observed in B4-based vaccine treatment [49]. 
Based on the antigenic heterogeneity among EV71 iso-
lates and the efficacy of multivalent VLP vaccine dem-
onstrated by the successful application of bivalent 
and tetravalent HPV vaccine, multivalent VLP-based 
vaccine has a great potential in the development of a 
safe and cost-effective anti-EV71 vaccine with broad 
cross-protection.
Conclusions
The co-expression of four EV71 capsid proteins in yeast 
resulted in effective production of EV71 VLPs, which 
elicited potent anti-EV71 antibody responses and pro-
tected neonatal mice against lethal viral challenges. Mul-
tivalent EV71 VLP-based vaccine has a great potential to 
be a safe and cost-effective vaccine candidate with broad 
cross-neutralizing activities against EV71 infection.
Methods
Construction of plasmids
The coding sequence of EV71 P1 protein of C4 sub-
genotype was optimized according to the codon usage 
for S. cerevisiae. DNA fragment encoding P1 protein 
was then synthesized. VP1 gene was amplified using 
primers VP1-BamH1 (5′-AAGGATCCATGGGTGA 
CAGAGTCGCCGAT-3′) and VP1-XhoI (5′-CCGCTC 
GAGTCATAAAGTAGTGATGGCT-3′. The PCR prod-
ucts were double-digested by XhoI and BamH1 and 
subsequently inserted into the vector pESC-URA (Inv-
itrogen) to construct pESC-VP1. VP4 gene was ampli-
fied using primers VP4-EcoR1 (5′-CCGGAATTCATGG 
GATCACAAGTTTCA-3′) and VP4-BglII (5′-GAAGA 
TCTCTTTAATGGGGCAGCCAT-3′). The PCR frag-
ments were further inserted into the vector plasmid 
pESC-VP1 at EcoR1 and BglII sites to yield pESC-VP1&4. 
VP2 gene was amplified using primers VP2-EcoRI 
(5′-CGGAATTCATGTCTCCATCTGCCGAAGCA-3′) 
and VP2-SacI (5′-AACGAGCTCCTGAGTAACGGC 
TTGCCT-3′). The amplified PCR products were then 
inserted into the vector pESC-HIS (Invitrogen) to con-
struct pESC-VP2 after double-digestion by EcoR1 and 
SacI. VP3 gene was amplified using primers VP3-BamHI 
(5′-CGGGATCCATGGGTTTTCCTACAGAATTG-3′) 
and VP3-XhoI (5′-CCGCTCGAGTTGTATTATTCCA 
GTCTG-3′). The amplified DNA fragments were then 
inserted into the plasmid pESC-VP2 at BamH1 and XhoI 
cutting sites to yield pESC-VP2&3.
Expression of recombinant protein in yeast
The recombinant plasmids pESC-VP1&4 and pESC-
VP2&3 were further co-transformed into yeast of 
INVSc1 strain (Invitrogen, USA) by using Sc EasyComp 
transformation kit (Invitrogen, USA) according to the 
instructions of the manufacturer. The yeast transfor-
mants were further selected onto a synthetic complete 
plates without uracil and histidine. Clonal isolates were 
then grown at 30 °C for 78 h in YPD containing 2 % galac-
tose to an optical density. After centrifugation, the har-
vesting cell pellets were broken with glass beads and cell 
lysates were analyzed for the expression of EV71 VP1.
Purification of VLPs
The yeast pellets were resuspended in sodium  phos-
phate  buffer (pH 7.2) supplemented with 1× 
rotease  inhibitor  cocktail. Yeast cells were broken by 
using high-pressure homogenizer (APV-2000, Den-
mark) with a pressure of 1500 Bar. 25 U/ml of benzonase 
(Merck, USA) was further added into the cell lysates and 
incubated for 1  h at room temperature. Cellular debris 
was then removed by centrifugation at 12,000g for 20 min 
at 4  °C. NaCl was added into the supernatant at a final 
concentration of 500  mM and polyethylene glycol 5000 
(Sigma-Aldrich, USA) was added at a final concentra-
tion of 10  % (w/v). After an overnight mixture at 4  °C, 
the supernatant was centrifuged at 12,000g for 20 min at 
4 °C and the pellets were resuspended into sodium phos-
phate  buffer (pH 7.2). Insoluble debris was removed by 
centrifugation at 10,000g for 10 min at 4 °C. The clarified 
supernatant was loaded onto the discontinuous sucrose 
gradient consisting of 15, 35 and 65 % sucrose that was 
dissolved in PBS buffer. After ultracentrifugation at 
100,000g using SW32Ti rotor (Beckman, USA) for 6  h, 
the white band between the interfaces of 15–35 % sucrose 
was collected and loaded onto discontinuous cesium 
chloride (CsCl) gradient (1.4, 1.33, 1.29 and 1.25  g/ml) 
and spun using SW32Ti rotor (Beckman, USA) for 21 h at 
100,000g. The VLP-containing fractions were harvested, 
diluted with sodium  phosphate  buffer, and ultracentri-
fuged at 34,000g for 6 h at 4 °C after dialyzed against low 
salt PBS buffer (pH 7.4). The pelleted VLPs were resus-
pended in PBS and concentration was measured using 
Bradford protein assay kit (Bio-Rad, USA).
Page 7 of 9Wang et al. BMC Res Notes  (2016) 9:42 
SDS‑PAGE and western blotting
The purified VLP samples were denatured by boiling for 
10  min and loaded onto SDS-PAGE (12  %) gel for elec-
trophoresis. The recombinant proteins were detected by 
Western blotting using a monoclonal antibody against 
VP2 (MAB979, Millipore, USA). Briefly, the proteins 
were transferred onto PVDF membrane, which were 
blocked with 2  % (w/v) BSA in TBS solution for 1  h at 
room temperature, and further washed three times with 
TBS containing 0.05  % (v/v) Tween 20. The membrane 
was then incubated with primary anti-VP1 and anti-VP2 
antibodies, respectively, for 1  h at 37  °C, and washed 
three times with TBS buffer. After incubation with the 
secondary goat anti-rabbit and goat anti-mouse anti-
bodies conjugated with fluorescent dyes: IRDye 800 CW 
(KPL, USA) for 45  min, blotting images were acquired 
using the Odyssey infrared imaging system (Li-COR Bio-
sciences, USA) and analyzed by the software provided by 
the manufacturer.
Electron microscopy
The formation of EV71VLPs was analyzed by electron 
microscopy as described previously [3]. Briefly, samples 
were adsorbed to carbon-coated copper grids and incu-
bated for 1  min. The grids were then negatively stained 
for 45  s with 2  % phosphotungstic acid after washing 
twice with PBS and visualized using an electron micro-
scope (H-7650, HITACHI, Japan).
Immunization of animals
Pathogen-free female BALB/c mice were purchased from 
Beijing HFK Bioscience Co. (Beijing, China). All animals 
were housed at pathogen-free conditions. Animal experi-
ments were performed according to the current experi-
mental protocols involving animal study approved by the 
Institutional Animal Care and Use Committee of Peking 
University. For mice experiments, five female BALB/c 
mice (6–8 weeks) per group were immunized with 20 μg/
mouse of one of the following samples: purified VLPs, 
denatured VLPs, beta-propiolactone-inactivated EV71 
virus (Bj08 strain), yeast cell lysate or PBS. The immuni-
zation was boosted 3 weeks later with the same dosages. 
QuickAntibody™ from KBQ Biotechnology Co. (Bei-
jing, China) was used as an adjuvant. Control group was 
immunized with PBS plus adjuvant. The blood samples 
were collected at week 0, 2, 5, 8 and the sera were inacti-
vated at 56 °C for 30 min and stored at −80 °C.
ELISA analysis
Inactivated EV71 virus were used as the coating antigen 
to titrate anti-EV71 IgG levels in the serum samples by 
sandwich enzyme-linked immunosorbent assay (ELISA) 
as described previously [3]. Briefly, 96-well plates were 
coated with polyclonal anti-EV71 antibody overnight at 
4  °C and blocked with the buffer containing 2  % (w/v) 
bovine serum albumin for 2 h at 37 °C. Inactivated EV71 
virus was added to the well and incubated for 2  h after 
washing thrice with the buffer (0.05 % (v/v) Tween 20 in 
PBS). The sera were analyzed at twofold serial dilutions 
by starting at 1:100. The plates were incubated at 37  °C 
for 1  h and washed thrice with buffer. HRP conjugated 
goat anti-mouse IgG (CWBIO, China) was then added 
into each well in a 1:2000 dilution, and incubated at 
37  °C for 1  h. The plates developed with TMB solution 
(Tiangen Biotech, China) in a dark room for 15 min after 
washing three times with buffer, and the reaction was 
stopped by adding 2 M H2SO4. The absorbance at 450 nm 
was evaluated using a microplatereader (Bio-Rad, USA).
In vitro neutralization assay
Neutralization assay was carried out as described previ-
ously [36]. Briefly, EV71 BJ08 (genotype C4) and BrCr-
TR (genotype A), were propagated in RD cells. The virus 
titers were determined in RD cells and expressed by 
the 50  % tissue culture infective dose (TCID50) accord-
ing to the Reed-Muench method. To measure the neu-
tralization titers, RD cells were cultured in the 96-well 
plates overnight until 60  % confluence. Serum samples 
were twofold serially diluted using Minimum Essential 
Medium (MEM, Gibco®) containing 2 % FBS and mixed 
with equal volume of EV71 (100 TCID50). After incuba-
tion overnight at 37  °C, the mixture was used to infect 
RD cells. The highest serum dilution, which could fully 
protect infected cells from developing cytopathic effects, 
was considered as neutralization titer.
Mouse protection assay
The protective efficacy of the immunized sera was eval-
uated by in  vivo infection experiments. Briefly, 50  μl of 
sera from mice immunized with recombinant VLPs, 
inactivated EV71, yeast cell lysate or PBS were incubated 
with 10 LD50 of EV71 BrCr-TR at 37 °C for 2 h. Groups 
of 1-day-old BALB/c suckling mice (n =  10 per group) 
were inoculated intraperitoneally (i.p.) with the mixture 
of virus and sera. All mice were monitored daily for the 
appearance of death for up to 16 days after inoculation.
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